KEYConversations: Latest advancement in systemic treatment outcomes for patients with advanced and recurrent endometrial cancer post meeting report
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PDF, 758 KB
The MSD and Eisai BGCS symposium: Latest advancements in systemic treatment outcomes for patients with advanced and recurrent endometrial cancer, with Consultant Medical Oncologist, Rebecca Kristeleit, took place on 30th June 2023 at the P&J Live Aberdeen. This informative session provided an overview of key outcomes from the KEYNOTE-775/Study 309 clinical trial, including:
- Patient characteristics and study design
- Key efficacy data
- Safety outcomes: two case studies of patients with endometrial cancer were discussed to provide an overview of the presentation, diagnosis, treatment options and adverse event management of those receiving KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib) combination therapy.
Finally, the ongoing real-world data collection for the regimen was discussed, including how clinicians can get involved, before closing with an informative Q&A session.
Read more about the session in the above report.
This symposium was a promotional meeting fully organised and funded by MSD and EISAI. MSD and Eisai products have been discussed at the meeting.
The views of the speaker are their own and do not represent the opinions of MSD.
KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation.1
Please refer to SPC for full prescribing information.
More information about KEYTRUDA® (pembrolizumab) in endometrial cancer
Reference
- KEYTRUDA Summary of Product Characteristics.
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
